Epstein File EFTA00447987: Session, CI and Treat (DS9)

Epstein Index›Documents›EFTA00447987

💨IMPACT LEVEL 1 — MEH

Epstein File EFTA00447987: Session, CI and Treat (DS9)

General DocumentDate unavailableEFTA004479871 keyword hits

1

views

0

shares

0

reactions

0

persons

3

keywords

5

excerpts

This document is a medical research summary describing the FOURIER study on PCSK9 inhibition presented at the 2017 American College of Cardiology Scientific Session in Washington, D.C. The excerpt includes clinical trial data comparing evolocumab and placebo groups, with specific patient numbers and statistical measures (hazard ratios and confidence intervals). The document discusses cardiovascular outcomes and treatment recommendations for LDL cholesterol management.

👤 Named in This Document

No named persons linked yet

🔑 Evidence Keywords

session CI treat

📋 Key Excerpts5

PersonKeyword

Excerpt 1

Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific **Session**

Excerpt 2

Presented at: American College of Cardiology 2017 Scientific **Session** in Washington, D.C.

Excerpt 3

For the primary study endpoint (which occurred in 1,344 patients in the evolocumab group and 1,563 in the placebo group; HR, 0.85; 95% **CI**, 0.79-0.92; P